ADmit Therapeutics
Marta Blanch Lozano has a solid background in Molecular Biology, with a PhD from Universitat de Barcelona. Marta has worked in various positions at different companies and institutions, focusing on assay development, research and teaching. Their experience includes roles such as Head of Assay Development at ADmit Therapeutics, Associate Professor at Universitat de Barcelona, and Postdoctoral positions at IDIBELL.
This person is not in the org chart
This person is not in any teams
ADmit Therapeutics
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer.